Efflux Pump Mediated Azole Resistance in Candida Albicans
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03659162|
Recruitment Status : Not yet recruiting
First Posted : September 6, 2018
Last Update Posted : September 6, 2018
|Condition or disease||Intervention/treatment|
|Fungal Infection||Drug: Azole Antifungal|
|Study Type :||Observational|
|Estimated Enrollment :||100 participants|
|Official Title:||Efflux Pump Mediated Azole Resistance in Candida Albicans Among Neutropenic Patients With Haematological Malignancies|
|Estimated Study Start Date :||February 17, 2019|
|Estimated Primary Completion Date :||April 10, 2019|
|Estimated Study Completion Date :||July 24, 2019|
neutropenic cancer patient recieving azoles .
neutropenic cancer patients that undergoing chemotherapy with prophylaxis with azoles and exhibit recurrent fungal infection so appropriate clinical specimen will taken for isolation & identification of causative agent & it's antimicrobial profile then identification of the mechanism of resistance by invitro technique then confirmed by real time pcr.
Drug: Azole Antifungal
oral gel & injections
- characterize the clinical Candida albicans strains isolated from neutropenic patients with Hematological Malignancies. [ Time Frame: 3 months ]isolation & identification of of Candida albicans by culturing on Sabouraud's Dextrose Agar (SDA) and CHROM Agar Candida then determination of antifungal susceptibility testing by Disk Diffusion test and determination of MIC by broth microdilution method to identify resistant Candida albicans strains to decrease hazard to these high risk group of patients.
- Determination if Ibuprofen could elicit a reversal of fluconazole resistance by interference with efflux pump activity. [ Time Frame: 2month ]reverting of resistance to fluconazole using Ibuprofen as efflux pump inhibitor detected by redetermination of MIC values in presence of a subinhibitory concentration of Ibuprofen.
- Testing new NS-IDs other than Ibuprofen as efflux pump inhibitor [ Time Frame: 3 months ]resistant Candida albicans strains will subject to broth microdilution in presence and absence of other NS-IDs.
- Uncover the molecular base of antifungal resistance in C. albicans clinical strains that could be reverted by ibuprofen [ Time Frame: 4 months ]quantification of gene expression of genes encoding for efflux pump (CDR1, CDR2 and MDR1) by real time pcrRT-PCR(q RT-PCR) The relative quantities of the target genes were normalized against ACT1 housekeeping gene expression and analysed using the comparative DDCt method, taking the amplification efficiency into consideration.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03659162
|Contact: . Ehsan Abdelsabor Hassan, Professorfirstname.lastname@example.org|
|Contact: Michael Nazmy Agban, Assistant Professoremail@example.com|